<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068145</url>
  </required_header>
  <id_info>
    <org_study_id>P05567</org_study_id>
    <secondary_id>2008-006650-18</secondary_id>
    <nct_id>NCT01068145</nct_id>
  </id_info>
  <brief_title>Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)</brief_title>
  <official_title>Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled, Incomplete Crossover, Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to evaluate the dose response of SCH 527123 in reducing inflammation from an&#xD;
      ozone-induced sputum neutrophilia in both healthy subjects and subjects with COPD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PD/PK: Dose response of SCH 527123 on ozone-induced sputum neutrophilia in healthy subjects (Part 1) and subjects with COPD (Part 2), measured by placebo-adjusted percent change in sputum neutrophil counts and absolute sputum neutrophil counts.</measure>
    <time_frame>Part 1, four treatment periods, Part 2 three treatment periods duration of the trial.</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Very low dose SCH 527123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose SCH 527123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose SCH 527123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose SCH 527123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match SCH 527123</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose SCH 527123 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose SCH 527123 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose SCH 527123 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 527123</intervention_name>
    <description>Very low dose SCH 527123, once daily for 7 days</description>
    <arm_group_label>Very low dose SCH 527123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 527123</intervention_name>
    <description>Low dose SCH 527123, once daily for 7 days</description>
    <arm_group_label>Low dose SCH 527123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 527123</intervention_name>
    <description>Medium dose SCH 527123, once daily for 7 days</description>
    <arm_group_label>Medium dose SCH 527123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 527123</intervention_name>
    <description>High dose SCH 527123, once daily for 7 days</description>
    <arm_group_label>High dose SCH 527123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules to match SCH 527123, once daily for 7 days</description>
    <arm_group_label>Placebo to match SCH 527123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 527123</intervention_name>
    <description>Low dose capsule SCH 527123, once daily for 14 days</description>
    <arm_group_label>Low dose SCH 527123 (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 527123</intervention_name>
    <description>Medium dose capsule SCH 527123, once daily for 14 days</description>
    <arm_group_label>Medium dose SCH 527123 (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 527123</intervention_name>
    <description>High dose capsule SCH 527123, once daily for 14 days</description>
    <arm_group_label>High dose SCH 527123 (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules to match SCH 527123, once daily for 14 days</description>
    <arm_group_label>Placebo (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1&#xD;
&#xD;
          -  Subject of either sex and of any race between the age of 18 and 55 years, with a BMI&#xD;
             (weight [kg]/height [m2]) between 19 and 32.&#xD;
&#xD;
          -  Subject must have a FEV1 ≥ 80 % of predicted value.&#xD;
&#xD;
          -  Subject must be nonsmoker (including cigarettes, cigars and pipes) or exsmoker who has&#xD;
             stopped smoking for at least 6 months (smoking history ≤ 5 pack years).&#xD;
&#xD;
          -  Subject's clinical laboratory tests (CBC, blood chemistry, urinalysis) must be within&#xD;
             normal limits. Subjects must have a neutrophil count of &gt;2.0 x 109/L. (also Part 2)&#xD;
&#xD;
          -  Subject must be free of any clinically significant disease that would interfere with&#xD;
             the study evaluations (also Part 2).&#xD;
&#xD;
          -  Screening ECG conduction intervals must be within gender specific normal range; QTcB&#xD;
             males ≤430 msec and females ≤450 msec (also Part 2).&#xD;
&#xD;
          -  Vital sign measurements must be: a) oral body temperature, between 35.0°C and 37.5°C;&#xD;
             b) systolic blood pressure, 90 to 140 mm Hg (160 mm Hg, Part 2); c) diastolic blood&#xD;
             pressure, 45 to 90 mm Hg (100 mm Hg, Part 2); d) pulse rate, 40 to 100 bpm.&#xD;
&#xD;
          -  Subject and partner(s) must be using an accepted method of contraception during the&#xD;
             trial through 2 months post-treatment (also Part 2).&#xD;
&#xD;
          -  Prior to randomization, subject must be a responder to ozone (also Part 2).&#xD;
&#xD;
        Part 2&#xD;
&#xD;
          -  Subject with a diagnosis of COPD for at least 1 year and FEV1 ≥65% of predicted value&#xD;
             post bronchodilation (measurement 30 minutes after 400 mcg salbutamol administration)&#xD;
             and FEV1/FVC of &lt;70%.&#xD;
&#xD;
          -  Subject of either sex and of any race between the age of 40 and 65 years, with a BMI&#xD;
             between 19 and 32.&#xD;
&#xD;
          -  Subject must be active or exsmoker (cigarettes, cigars and/or pipes).&#xD;
&#xD;
          -  Subject must have a normal exercise stress test (no clinically significant ECG&#xD;
             findings).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part 1 and Part 2&#xD;
&#xD;
          -  Female subject who is pregnant, intends to become pregnant (within 3 months of ending&#xD;
             the study), or is breastfeeding.&#xD;
&#xD;
          -  Subject with history of seasonal or perennial allergic rhinitis (ie, season for&#xD;
             specific allergen).&#xD;
&#xD;
          -  Subject who has an allergy or a contraindication to excipients in placebo or SCH&#xD;
             527123 formulations or salbutamol.&#xD;
&#xD;
          -  Surgical or medical condition (history or presence) which might alter the ADME of the&#xD;
             drug: a) inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding; b)&#xD;
             major gastrointestinal tract surgery, ie, gastrectomy, gastroenterostomy, or bowel&#xD;
             resection; c) pancreatic injury or pancreatitis; d) liver disease or injury; e)&#xD;
             impaired renal function indicated by abnormal creatinine, urinary albumin, BUN/urea or&#xD;
             clinical significant urinary cellular constituents (eg, cast); or f) urinary&#xD;
             obstruction or difficulty in voiding.&#xD;
&#xD;
          -  Subject who has any infectious disease within 4 weeks prior to drug administration.&#xD;
&#xD;
          -  Subject who is positive for hepatitis B surface antigen, hepatitis C antibodies or&#xD;
             HIV.&#xD;
&#xD;
          -  Subject who has a positive screen for drugs with a high potential for abuse (Screening&#xD;
             and/or treatment period).&#xD;
&#xD;
          -  Subjects with a history of mental instability or who have been treated for mood&#xD;
             disorder.&#xD;
&#xD;
          -  Subject with a history of alcohol or drug abuse in the past 2 years.&#xD;
&#xD;
          -  Subject who has donated blood in the past 60 days.&#xD;
&#xD;
          -  Subject who has demonstrated allergic reactions (eg, food, drug, atopic reactions or&#xD;
             asthmatic episodes) which may interfere with ability to participate in the trial.&#xD;
&#xD;
          -  Subject who has previously received SCH 527123 (Part 2 only)&#xD;
&#xD;
          -  Subject who has received any of the following treatments more recently than indicated&#xD;
             washout period prior to Baseline:&#xD;
&#xD;
               -  Parts 1 and 2: OTC medications (excluding paracetamol), 14 days.&#xD;
&#xD;
               -  Part 1: prescription medications, 14 days; investigational drugs, 30 days.&#xD;
&#xD;
               -  Part 2: vitamins and herbal supplements, 14 days; statins, 4 weeks; steroids&#xD;
                  (inhaled), 4 weeks; steroids (oral and dermal), 8 weeks; antibiotics, 6 weeks;&#xD;
                  leukotriene antagonists, 4 weeks; NSAIDS, 2 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Germany</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J. 2010 Mar;35(3):564-70. doi: 10.1183/09031936.00048509. Epub 2009 Jul 30.</citation>
    <PMID>19643947</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 11, 2010</study_first_submitted>
  <study_first_submitted_qc>February 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

